Biotherapeutics for ischemic, hypoxic, and anemic diseases in oncology, cardiovascular and stroke diseases, diabetes, trauma, surgery, and sickle cell crises. Focused on overcoming biochemical shortcomings in prior efforts at oxygen and nitric oxide delivery.